(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 15.03% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.8%.
Pulmonx's revenue in 2025 is $87,473,000.On average, 2 Wall Street analysts forecast LUNG's revenue for 2025 to be $3,912,629,049, with the lowest LUNG revenue forecast at $3,904,980,119, and the highest LUNG revenue forecast at $3,920,277,979. On average, 2 Wall Street analysts forecast LUNG's revenue for 2026 to be $4,618,142,210, with the lowest LUNG revenue forecast at $4,534,205,266, and the highest LUNG revenue forecast at $4,702,079,154.
In 2027, LUNG is forecast to generate $5,448,654,992 in revenue, with the lowest revenue forecast at $5,229,050,182 and the highest revenue forecast at $5,668,259,802.